Andere Sprachen Korro Bio, Inc.

Aktien

A3EV9N

US5009461089

KRRO

Verzögert Nasdaq Andere Börsenplätze 22:00:00 02.05.2024			% 5 Tage	% 1. Jan.
58,22 ^USD	-4,54 %		-0,53 %	+21,47 %

24.04.	Korro Bio Insider kaufte Aktien im Wert von $999,992, laut einer aktuellen SEC Einreichung	MT
24.04.	Korro Bio Insider kaufte Aktien im Wert von $999,992, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	24.04.
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	24.04.
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	24.04.
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	24.04.
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	24.04.
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	24.04.
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	24.04.
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.	22.04.
Korro Announces $70 Million Private Placement	18.04.
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.	17.04.
Korro to Participate in Upcoming Investor Conferences	01.04.
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress	26.03.
North American Morning Briefing : Stocks Struggle After New Records	22.03.
North American Morning Briefing : Inflation -2-	15.03.
Korro Bio: Development and Application of Graph Neural Networks to Design Guide Oligonucleotides that Promote RNA Editing	13.03.
Korro to Present at the TD Cowen 44th Annual Health Care Conference	27.02.
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio	18.01.
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference	04.01.
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency	07.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Korro Bio, Inc.

Aktien

A3EV9N

US5009461089

KRRO

Andere Sprachen

Filter